Kubota et al. reported that daily anti-CSF-1R therapeutic antibody AFS98 treatment (50 mg/kg) reduced the number of peritumoral LYVE-1+ macrophages in an implanted osteosarcoma (AX cells) mice model and reduced vascularization, lymphangiogenesis and tumor growth [18]. This evidence concerns the gene CSF1R and neoplasm.